🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. ,4-diaminopyridine

    Ultragenyx UK Limited

    Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

    phase 3 small molecule completed

    1 trial

  2. -, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927

    Janssen-Cilag International N.V.

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  3. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 3 other active

    1 trial

  4. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis, Non-Radiographic

    phase 3 small molecule active

    1 trial

  5. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  6. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  7. Botulinum Toxin type A (intradermal / submucosal injection at pain area)

    The First People's Hospital of Lianyungang

    Trigeminal Neuralgia

    phase 3 small molecule active

    1 trial

  8. Bufei Yishen granule

    Henan University of Traditional Chinese Medicine

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  9. CISPLATIN, FLUOROURACIL, MITOMYCIN, CAPECITABINE, CAPECITABINE, DOCETAXEL

    CERO THERAPEUTICS HOLDINGS, INC.

    locally advanced anal squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  10. Carbetocin

    Acadia Pharmaceuticals B.V.

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials

  11. Carbetocin Nasal Spray

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  12. Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  13. Chirhostim

    The George Institute

    Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

    phase 3 small molecule active

    1 trial

  14. Clonidine HCl Mucoadhesive Buccal Tablet

    Monopar Therapeutics

    Chemoradiotherapy-Induced Severe Oral Mucositis

    phase 3 small molecule terminated

    1 trial

  15. DCCR

    SOLENO THERAPEUTICS INC

    Prader-Willi Syndrome

    phase 3 small molecule active

    4 trials

  16. EVEROLIMUS

    Novartis Pharmaceuticals

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial

  17. Ear pills

    Universal Integrated

    Intradialytic Hypotension

    phase 3 small molecule active

    1 trial

  18. Elective nodal irradiation (ENI)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma

    phase 3 other active

    1 trial

  19. Estradiol

    Teva Pharma GmbH

    Dyspareunia

    phase 3 small molecule completed

    1 trial

  20. Estradiol

    TherapeuticsMD

    Vulvovaginal Atrophy

    phase 3 small molecule completed

    1 trial

  21. Estradiol

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    2 trials

  22. Estradiol Vaginal Tablets 10 mcg

    Amneal Pharma Europe Ltd

    Atrophic Vaginitis Due to Menopause

    phase 3 small molecule completed

    1 trial

  23. Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Primary Dysmenorrhea

    phase 3 small molecule completed

    1 trial

  24. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Ningbo Cancer Hospital

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources